Kura Oncology (KURA) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Latigo Biotherapeutics is the larger company by market cap ($1.06 billion vs $943.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | LTGO |
|---|---|---|
| Share price | $10.60 | $16.00 |
| Market cap | $942.98M | $1.06B |
| 1-day change | +0.76% | +8.18% |
| YTD return | +2.02% | — |
| 1-year return | +3.41% | — |
| 5-year return | -41.18% | — |
| EPS (TTM) | $-3.37 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.90 | $25.93 |
| 52-week low | $7.36 | $14.60 |
| Distance from 52-week high | -23.74% | -38.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +200.47% | +226.56% |
| Average volume | 1.78M | 391.26K |
| Shares outstanding | 88.96M | 66.30M |
| Employees | 260 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
KURA vs LTGO FAQ
Which is bigger, Kura Oncology or Latigo Biotherapeutics?
Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $1.06B compared with $942.98M for Kura Oncology (KURA).
Are Kura Oncology and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.